TGF-β1:: a novel target for cardiovascular pharmacology

被引：37

作者：

Redondo, Santiago ^{[1
]}

Santos-Gallego, Carlos G. ^{[1
]}

Tejerina, Teresa ^{[1
]}

机构：

[1] Univ Complutense Madrid, Sch Med, Dept Pharmacol, E-28040 Madrid, Spain

来源：

CYTOKINE & GROWTH FACTOR REVIEWS | 2007年 / 18卷 / 3-4期

关键词：

cardiovascular; cell communication; cytokines; signal transduction; growth factors;

D O I：

10.1016/j.cytogfr.2007.04.005

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Transforming growth factor beta-1 (TGF-beta 1) plays a key role in cardiovascular disease by a process which allows the loss of its protective properties. The first therapeutic attempt to restore its function by selectively designed novel drugs are being made. In addition, it has been recognized that the TGF-beta 1 pathway is involved in the vascular mechanism of action of some current clinical drugs, such as acetylsalicylic acid, thiazolidinediones and statins. The aim of this paper is to review the possible value of TGF-beta 1 as both a disease marker and a therapeutical target for cardiovascular disease. (c) 2007 Elsevier Ltd. All rights reserved.

引用

页码：279 / 286

页数：8

共 79 条

[1] Natural regulatory T cells control the development of atherosclerosis in mice [J].

Ait-Oufella, H ;

Salomon, BL ;

Potteaux, S ;

Robertson, AKL ;

Gourdy, P ;

Zoll, J ;

Merval, R ;

Esposito, B ;

Cohen, JL ;

Fisson, S ;

Flavell, RA ;

Hansson, GK ;

Klatzmann, D ;

Tedgui, A ;

Mallat, Z .

NATURE MEDICINE, 2006, 12 (02) :178-180

[2] Structurally different RGTAs modulate collagen-type expression by cultured aortic smooth muscle cells via different pathways involving fibroblast growth factor-2 or transforming growth factor-β1 [J].

Alexakis, C ;

Mestries, P ;

Garcia, S ;

Petit, E ;

Barbier, V ;

Papy-Garcia, D ;

Sagot, MA ;

Barritault, D ;

Caruelle, JP ;

Kern, P .

FASEB JOURNAL, 2004, 18 (07) :1147-+

[3] Making sense of latent TGFβ activation [J].

Annes, JP ;

Munger, JS ;

Rifkin, DB .

JOURNAL OF CELL SCIENCE, 2003, 116 (02) :217-224

[4] A critical role of tropomyosins in TGF-β regulation of the actin cytoskeleton and cell motility in epithelial cells [J].

Bakin, AV ;

Safina, A ;

Rinehart, C ;

Daroqui, C ;

Darbary, H ;

Helfman, DM .

MOLECULAR BIOLOGY OF THE CELL, 2004, 15 (10) :4682-4694

[5] Add-on anti-TGF-β antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat [J].

Benigni, A ;

Zoja, C ;

Corna, D ;

Zatelli, C ;

Conti, S ;

Campana, M ;

Gagliardini, E ;

Rottoli, D ;

Zanchi, C ;

Abbate, M ;

Ledbetter, S ;

Remuzzi, G .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (07) :1816-1824

[6] Regulation of the cytoskeleton: An oncogenic function for CDK inhibitors? [J].

Besson, A ;

Assoian, RK ;

Roberts, JM .

NATURE REVIEWS CANCER, 2004, 4 (12) :948-955

[7] TGF-β-induced RhoA and p160ROCK activation is involved in the inhibition of Cdc25A with resultant cell-cycle arrest [J].

Bhowmick, NA ;

Ghiassi, M ;

Aakre, M ;

Brown, K ;

Singh, V ;

Moses, HL .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (26) :15548-15553

[8] Mechanisms of disease:: Role of transforming growth factor β in human disease. [J].

Blobe, GC ;

Schiemann, WP ;

Lodish, HF .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (18) :1350-1358

[9] Transforming growth factor-βs and vascular disorders [J].

Bobik, Alex .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (08) :1712-1720

[10] Progressive transforming growth factor β1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor [J].

Bonniaud, P ;

Margetts, PJ ;

Kolb, M ;

Schroeder, JA ;

Kapoun, AM ;

Damm, D ;

Murphy, A ;

Chakravarty, S ;

Dugar, S ;

Higgins, L ;

Protter, AA ;

Gauldie, J .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 171 (08) :889-898

← 1 2 3 4 5 6 7 8 →